Quality of life in patients treated with aflibercept and FOLFIRI for metastatic colorectal cancer: interim analysis with focus on therapy lines of the non -interventional study QoLiTrap (AlO-LQ-0113)

被引：0
|
作者：
Hofheinz, R. [1 ]
Scholten, F. [2 ]
Derigs, H. [2 ]
Thaler, J. [3 ]
von Moos, R. [1 ,4 ]
机构：
[1] Univ Hosp Mannheim, Mannheim, Germany
[2] Klinikum Frankfurt Hoechst GmbH, Frankfurt, Germany
[3] Klinikum Wels Grieskirchen GmbH, Wels, Austria
[4] Kantonsspital Graubuenden, Chur, Switzerland
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 026
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [31] The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study
    D'Arcangelo, M.
    Buonerba, C.
    Avallone, A.
    Dazzi, C.
    Frassineti, G.
    Tamberi, S.
    Tassinari, D.
    Aprile, G.
    Granetto, C.
    Bonetti, A.
    Vecchiarelli, S.
    Cappuzzo, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [32] Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.
    Bordonaro, Roberto
    Sobrero, Alberto F.
    Frassineti, Luca
    Ciuffreda, Libero
    Aprile, Giuseppe
    Thomas, Anne L.
    Moore, Yan
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Taieb, Julien
    Ferry, David Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumab.
    Sobrero, Alberto F.
    Bordonaro, Roberto
    Bencardino, Katia
    Pietrantonio, Filippo
    Bauer, Stefan
    Taieb, Julien
    Garreau-Laporte, Pascale
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Lledo, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [34] Aflibercept plus FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure: 4th interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP/AFEQT studies)
    Kroening, H.
    Bauer, S.
    Frassineti, L.
    Di Bartolomeo, M.
    Thomas, A. L.
    Taieb, J.
    Lledo, G.
    Moore, Y.
    Zilocchi, C.
    Brette, S.
    Sobrero, A.
    Bordonaro, R.
    Heinemann, V
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 106 - 107
  • [35] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients age 65 and older.
    Bordonaro, Roberto
    Frassineti, Luca
    Ciuffreda, Libero
    Aprile, Giuseppe
    Thomas, Anne L.
    Vishwanath, Raghu
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Taieb, Julien
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).
    Ferry, David Raymond
    Sobrero, Alberto F.
    Bordonaro, Roberto
    Siena, Salvatore
    Pietrantonio, Filippo
    Bauer, Stefan
    Taieb, Julien
    Garreau-Laporte, Pascale
    Brette, Sandrine
    Dochy, Emmanuelle
    Lledo, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [37] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B).
    Sobrero, Alberto F.
    Bordonaro, Roberto
    Bencardino, Katia
    Pietrantonio, Filippo
    Bauer, Stefan
    Taieb, Julien
    Garreau-Laporte, Pascale
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Lledo, Gerard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [38] Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP).
    Rivera, Fernando
    Marques, Eduardo Polo
    Aranda, Enrique
    Fernandez-Martos, Carlos
    Munoa, Adelaida La Casta
    Guillen, Carmen
    Lopez, Rafael
    Gil, Silvia
    Lema, Laura
    Aparicio, Jorge
    Villacampa, Mercedes Martinez
    Pisa, Aleydis
    Borrega, Pablo
    Lopez-Vivanco, Guillermo
    Alfonso, Pilar Garcia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [39] Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild type metastatic colorectal cancer (mCRC) treated with first-line (1L) panitumumab (PAN) plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE
    Reiser, M.
    Uhlig, J.
    Jacobasch, L.
    Mueller, L.
    Schuch, A.
    Serrer, L.
    de Buhr, R.
    Siebenbach, H. U.
    Goehler, T.
    Schroeder, K.
    Semsek, D.
    Koehler, A.
    Stuebs, P.
    Potthoff, K. M.
    Marschner, N. W.
    ANNALS OF ONCOLOGY, 2023, 34 : S445 - S445
  • [40] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.
    Bordonaro, Roberto
    Frassineti, Giovanni Luca
    Ciuffreda, Libero
    Aprile, Giuseppe
    Thomas, Anne
    Vishwanath, Raghu L.
    Zilocchi, Chiara
    Dochy, Emmanuelle
    Taieb, Julien
    Sobrero, Alberto F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345